0.7763
price up icon5.48%   0.0403
pre-market  プレマーケット:  .77   -0.0063   -0.81%
loading
前日終値:
$0.736
開ける:
$0.76
24時間の取引高:
3.59M
Relative Volume:
0.57
時価総額:
$165.88M
収益:
$52.29M
当期純損益:
$-134.84M
株価収益率:
-1.0351
EPS:
-0.75
ネットキャッシュフロー:
$-117.11M
1週間 パフォーマンス:
+5.16%
1か月 パフォーマンス:
-10.42%
6か月 パフォーマンス:
-35.84%
1年 パフォーマンス:
+52.19%
1日の値動き範囲:
Value
$0.71
$0.78
1週間の範囲:
Value
$0.67
$0.8058
52週間の値動き範囲:
Value
$0.304
$3.179

Sangamo Therapeutics Inc Stock (SGMO) Company Profile

Name
名前
Sangamo Therapeutics Inc
Name
セクター
Healthcare (1153)
Name
電話
(510) 970-6000
Name
住所
501 CANAL BLVD., RICHMOND, CA
Name
職員
183
Name
Twitter
@sangamotx
Name
次回の収益日
2025-03-17
Name
最新のSEC提出書
Name
SGMO's Discussions on Twitter

SGMO を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
SGMO
Sangamo Therapeutics Inc
0.7763 165.88M 52.29M -134.84M -117.11M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
490.47 128.67B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
585.49 60.99B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
599.87 36.96B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
236.75 29.89B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
252.77 25.74B 3.81B -644.79M -669.77M -6.24

Sangamo Therapeutics Inc Stock (SGMO) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-12-13 アップグレード Truist Hold → Buy
2024-12-10 繰り返されました H.C. Wainwright Buy
2023-11-03 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2023-04-28 ダウングレード BofA Securities Neutral → Underperform
2023-02-27 アップグレード Wedbush Neutral → Outperform
2023-01-06 ダウングレード BofA Securities Buy → Neutral
2022-06-13 再開されました Wedbush Neutral
2021-05-04 開始されました RBC Capital Mkts Outperform
2021-01-07 再開されました Guggenheim Neutral
2021-01-06 開始されました Stifel Hold
2020-12-16 再開されました H.C. Wainwright Buy
2020-09-08 開始されました BofA Securities Buy
2020-07-07 開始されました SunTrust Buy
2019-08-26 開始されました H.C. Wainwright Buy
2018-11-14 ダウングレード JP Morgan Overweight → Neutral
2018-11-09 ダウングレード Guggenheim Buy → Neutral
2018-10-10 開始されました Guggenheim Buy
2018-06-20 開始されました BofA/Merrill Buy
2017-11-15 アップグレード Piper Jaffray Neutral → Overweight
2017-06-22 再開されました Jefferies Buy
2016-11-01 ダウングレード Wedbush Outperform → Neutral
2016-10-19 ダウングレード Piper Jaffray Overweight → Neutral
2015-12-04 開始されました Wells Fargo Outperform
2015-10-23 再開されました Jefferies Buy
2013-05-03 開始されました BioLogic Equity Research Sell
2011-02-23 繰り返されました JMP Securities Mkt Outperform
2010-07-29 繰り返されました Wedbush Outperform
2009-10-19 開始されました Brean Murray Sell
2009-10-07 繰り返されました Leerink Swann Outperform
2009-08-25 繰り返されました JMP Securities Mkt Outperform
すべてを表示

Sangamo Therapeutics Inc (SGMO) 最新ニュース

pulisher
Apr 22, 2025

Form 4Statement of changes in beneficial ownership of securities - ADVFN

Apr 22, 2025
pulisher
Apr 15, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly to Deliver Genomic Medicines for Diseases of the Central Nervous System - Zenopa

Apr 15, 2025
pulisher
Apr 13, 2025

Sangamo announces capsid license agreement with Eli Lilly - MSN

Apr 13, 2025
pulisher
Apr 07, 2025

Lilly, Sangamo Enter Capsid License Agreement - Contract Pharma

Apr 07, 2025
pulisher
Apr 04, 2025

Another rebound as Sangamo inks $1.4B capsid deal with Lilly - BioWorld MedTech

Apr 04, 2025
pulisher
Apr 04, 2025

Lilly Licenses Sangamo’s Capsid Technology For CNS Gene Therapy - insights.citeline.com

Apr 04, 2025
pulisher
Apr 04, 2025

Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal (SGMO) - Seeking Alpha

Apr 04, 2025
pulisher
Apr 04, 2025

Sangamo Thera enters critical deal with Lilly - The Pharma Letter

Apr 04, 2025
pulisher
Apr 04, 2025

Lilly Throws Sangamo a Lifeline With Pact Worth Potential $1.4B+ - BioSpace

Apr 04, 2025
pulisher
Apr 04, 2025

Lilly throws lifeline to Sangamo with $1.4bn licensing deal - pharmaphorum

Apr 04, 2025
pulisher
Apr 04, 2025

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket - Benzinga

Apr 04, 2025
pulisher
Apr 03, 2025

RH, FIVE, SGMO, BAC, TSLA: Top 5 Trending Stocks TodayFive Below (NASDAQ:FIVE), Bank of America (NYSE:BAC) - Benzinga

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Therapeutics (SGMO) Signs Major Licensing Deal with Eli Lilly - GuruFocus

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Therapeutics (SGMO) Surges on Licensing Deal with Eli Li - GuruFocus

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo licenses brain-targeting capsid to Lilly in $1.4 billion deal - Investing.com Canada

Apr 03, 2025
pulisher
Apr 03, 2025

Struggling Sangamo's brain-penetrating drug delivery tech attracts Eli Lilly in potential $1.4 billion pact - The Business Journals

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Therapeutics Announces Capsid License Agreement With Lilly To Deliver Genomic Medicines For Diseases Of The Central Nervous System - MarketScreener

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Therapeutics Stock Surges After The Bell: What's Going On? - Benzinga

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Signs Capsid License Deal With Eli Lilly; Shares Rise After Hours - MarketScreener

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal By Investing.com - Investing.com South Africa

Apr 03, 2025
pulisher
Apr 03, 2025

Sangamo Therapeutics stock soars on Lilly licensing deal - Investing.com

Apr 03, 2025
pulisher
Apr 02, 2025

Sangamo Therapeutics, Inc. (SGMO) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

5 Best Stem Cell Companies to Invest In (April 2025) - Securities.io

Apr 02, 2025
pulisher
Mar 31, 2025

Hunter Syndrome Treatment Market Generated Opportunities, - openPR.com

Mar 31, 2025
pulisher
Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: DelveInsight Analysis | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics - Barchart

Mar 20, 2025
pulisher
Mar 20, 2025

Fabry Disease Market Growth Projections 2023-2032: - openPR

Mar 20, 2025
pulisher
Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Sangamo Therapeutics’ SWOT analysis: gene therapy stock faces cash crunch amid pipeline progress - Investing.com India

Mar 19, 2025
pulisher
Mar 19, 2025

Truist Removes Price Target From Sangamo Therapeutics, Keeps Buy Rating; Price Target Had Been $5 - MarketScreener

Mar 19, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results - Zenopa

Mar 18, 2025
pulisher
Mar 18, 2025

8 Analysts Assess Sangamo Therapeutics: What You Need To Know - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 18, 2025
pulisher
Mar 18, 2025

US Futures Show Caution Among Investors Ahead Of FOMC Meeting: Analysts Say Only Certainty Is That 'Things Will Remain Uncertain For The Time Being' - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

IHS Holding, HealthEquity And 3 Stocks To Watch Heading Into Tuesday - Benzinga

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... - Yahoo

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ... By GuruFocus - Investing.com Canada

Mar 18, 2025
pulisher
Mar 18, 2025

Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - GuruFocus.com

Mar 18, 2025
pulisher
Mar 18, 2025

Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 17, 2025

Sangamo: Q4 Earnings Snapshot - mySA

Mar 17, 2025
pulisher
Mar 17, 2025

Earnings call transcript: Sangamo Therapeutics Q4 2024 reveals minor EPS miss - Investing.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics Q4 2024 Earnings: EPS of -$0.11 Misses Esti - GuruFocus.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo: Q4 Earnings Snapshot -March 17, 2025 at 04:36 pm EDT - Marketscreener.com

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics earnings missed, revenue fell short of estimates By Investing.com - Investing.com Canada

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics shares fall as Q4 results miss estimates By Investing.com - Investing.com Australia

Mar 17, 2025
pulisher
Mar 17, 2025

Sangamo Therapeutics shares fall as Q4 results miss estimates - Investing.com India

Mar 17, 2025

Sangamo Therapeutics Inc (SGMO) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$20.27
price up icon 1.00%
$71.24
price up icon 2.49%
$32.19
price up icon 0.00%
$27.35
price up icon 8.45%
$104.68
price up icon 2.82%
biotechnology ONC
$252.77
price up icon 10.27%
大文字化:     |  ボリューム (24 時間):